Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Explore essential mental health support strategies for older adults with cancer, addressing grief, community resources, and ...

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

Nurses should be familiar with PET scan protocol and what to ask patients with lung and bone cancers before administering ...

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, ...

C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain ...

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in ...